The TEMPLE study presented at ESMO 2023

​Last week the TEMPLE study (Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy) was presented at the European Society for Medical Oncology (ESMO) 2023 annual conference in Madrid. The trial-in-progress poster was presented by Christine Federspiel Secher, MD, PhD-student. 




The TEMPLE study is an ongoing investigator-initiated phase 1 and phase 2 study conducted at the Phase 1 Unit at Rigshospitalet. The project is a completely novel strategy for improving response rates to immune checkpoint inhibitors by applying an innovative thiopurine combination to increase the mutational burden, presence of neoepitopes and thus proportion of patients with incurable solid cancers that respond to treatment with immune checkpoint inhibitors.


Current status of the study

The TEMPLE study was initiated in September 2022 and currently 12 patients have been included in the study. RP2D has been determined and recruitment for phase 2 has begun.


Link to presented poster


Responsible editor
Webgruppen på Rigshospitalet